课题基金 / 基金详情

PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress

PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress
PAC1 受体拮抗剂作为慢性应激相关抑郁症和动脉粥样硬化的潜在治疗方法
批准号：
10916021
负责人：
Juan Marugan
金额：
$31.01万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10916021
关键词：
AtherosclerosisBiological AssayBiologyCell LineCellsChronic stressCollaborationsDiseaseExtramural ActivitiesFollow-Up StudiesGoalsInformaticsMental DepressionModelingNeuroblastomaPACAPR-1 proteinPharmaceutical ChemistryPhenotypeProcessReporterResearchResearch PersonnelSynthesis ChemistryTestingTranslationsUnited States National Institutes of HealthValidationWorkantagonistassay developmentdrug developmentdrug discoveryhigh throughput screeninglead optimizationmolecular modelingneuroblastoma cellnew technologynovelscreeningsmall moleculesmall molecule therapeuticstherapeutic developmenttoolvirtual screening

项目摘要

项目成果

Juan Marugan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
During this period, a cell-based assay to examine PAC1 activity in neuroblastoma cells was used for high-throughput screening to test approximately 4000 compounds. An additional 200 compounds selected through molecular modeling and virtual screening studies were also tested for ability to antagonize PAC1R. The team has performed follow up studies on a set of the most promising compounds from screening. Additional high-throughput screening utilizing the neuroblastoma reporter cell line is being considered.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of the relaxin 1 receptor
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
HTS Assay for Identification of Compounds that Reduce PNC Prevalence
海外基金